SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spacecoin is a satellite-based decentralized internet network that aims to provide reliable, permissionless connectivity across the globe. It is building a constellation of blockchain-enabled small satellites in low-Earth orbit to transmit data back to the Earth without heavily relying on traditional internet infrastructure such as cell towers and fiber-optic cables. The goal is to provide a reliable lifeline connection for the 2.6 billion people globally who have never connected to the Internet and an additional 3.5 billion who live with restricted access.  Spacecoin plans to offer services in its target countries of Nigeria, Indonesia, and India for as low as $1-2 per month per user. The network works as an open system where anyone can add satellites. The first satellite launched in December 2024, with three more planned for October 2025.

Spacelens

Investors are actively discussing the anticipated SpaceX IPO and its broader influence on the aerospace and DePIN sectors, leading to significant speculation around related partnerships and infrastructure projects. Community sentiment remains polarized as traders weigh the potential for a major market pivot against concerns regarding insider activity and the centralization of influence within the space technology industry.

RAIN is a decentralized, daily rewarding coin.

Rain Coin

Rain Coin is generating buzz for its community-driven, decentralized design, which uses a 1% reflection tax and a daily automated 'Thunderstorm' event to reward holders directly in their wallets. Supporters frequently highlight its ultra-scarce supply and focus on sustainable, long-term yield over speculative price action as key differentiators in the memecoin sector.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing market attention as a core infrastructure play for autonomous on-chain AI agents within the Base ecosystem, with investors closely watching its revenue-generating capabilities and utility-driven model. While some community members are actively accumulating during current price fluctuations, others are debating the timing of a potential breakout based on the project's ongoing developer updates and ecosystem expansion.

KAIO provides institutional-grade real-world asset (RWA) tokenization infrastructure that seamlessly connects traditional investment funds with digital capital markets. Through its purpose-built protocol, KAIO enables leading global asset managers to issue and distribute regulated tokenized funds across multiple high-performance blockchain networks — including Ethereum, Sei, Hedera, Solana, Aptos, and others — significantly expanding global access to institutional-quality real-world asset strategies for qualified investors.   By tokenizing feeder structures and shares in flagship funds, KAIO brings onchain access to proven strategies such as the BlackRock ICS US Dollar Liquidity Fund (one of the world’s largest institutional money market funds), the Brevan Howard Master Fund, Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE) via the HL SCOPE Access Fund, and Laser Digital’s Laser Carry Fund (LCF), among others. These tokenized vehicles deliver secure, compliant exposure to money market, macro, private credit, and alternative strategies while unlocking new levels of programmability, composability, and 24/7 liquidity in DeFi environments.

KAIO

KAIO is generating intense community interest as traders focus on its potential role in the RWA sector and track technical support levels for a possible reversal. Many are actively discussing accumulation strategies and anticipating a significant breakout as the asset maintains high trending status.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is driving intense investor conversation ahead of the ASCO 2026 conference, where new late-breaking data for its lead candidate, ivonescimab, is expected to provide key insights into its potential to reshape oncology standards. The community is heavily focused on the drug's performance compared to existing immunotherapy benchmarks, with bulls emphasizing the clinical significance of plenary presentation slots as a major de-risking catalyst, while others remain cautious and focused on the risks associated with Phase 3 trial results and long-term regulatory milestones.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending as investors weigh its potential role in AI identity verification, with the community actively debating whether it serves as a critical infrastructure layer or a speculative asset. Sentiment is heavily influenced by its connection to OpenAI and ongoing discussions about 'proof-of-humanity' in an increasingly automated digital landscape.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending as institutional interest remains high, evidenced by strong, uninterrupted inflows into spot ETFs and growing market optimism surrounding its utility in global payment systems. Community discussions are heavily focused on the potential impact of legislative developments like the Clarity Act and how these regulatory milestones could accelerate the asset's adoption and financial integration.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is trending as investors digest the launch of a major new sports streaming joint venture with Disney and Warner Bros. Discovery. The community is actively debating the strategic implications of this platform for cable dominance, while some discussions have become polarized by off-topic political commentary and broader sector criticism.

Abrdn Palladium ETF Trust - Units of fractional undivided beneficial interest

abrdn ETF - abrdn Physical Palladium Shares ETF

The PALL ETF is trending as investors debate whether the asset is finally carving out a long-term bottom or facing continued downside following a period of persistent selling pressure. Community discussion remains polarized, with some traders leveraging volatility to sell cash-secured puts, while technical analysts closely monitor Elliott Wave structures and key support levels to determine if the metal can sustain a rebound.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending due to the strategic restructuring of its oncology business and a breakthrough therapy designation for its KRAS G12C inhibitor, which is being developed to bolster its cancer portfolio ahead of future patent expirations. Community discussion is heavily focused on these pipeline developments, with significant debate regarding the competitive landscape for its flagship drug Keytruda and potential acquisition targets in the biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Biotech Supercycle Is Here: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders. $LLY, $NVO, $NTHI, $BAC, $STT, $BCS, $IMVT, $SRPT, $MRNA, $CRSP

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

Key PointsCRISPR Therapeutics has an approved product and several gene editing medicines in development...

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a...

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

Key PointsBullish sentiment for CRISPR Therapeutics makes sense given the potential catalysts ahead...

VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 6.1%  - What's Next?

CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 6.1% - Here's Why...

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.20	--	--	N/A
Q1 '26	-$1.22	-$1.28	-5.05%	MISSED
Q4 '25	-$1.16	-$1.37	-17.81%	MISSED
Q3 '25	-$1.26	-$1.17	7.15%	BEAT
Q2 '25	-$1.40	-$2.40	-71.24%	MISSED

CRSP
CRISPR Therapeutics AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Compact View

Latest CRSP News

CRSPCRISPR Therapeutics AG